CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition(s):Multiple Myeloma; Plasma Cell LeukemiaLast Updated:April 20, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple Myeloma; Plasma Cell LeukemiaLast Updated:April 20, 2023Recruiting
Condition(s):Medullary Thyroid CarcinomaLast Updated:March 20, 2020Completed
Condition(s):Acute Coronary Syndrome; Chest PainLast Updated:December 17, 2020Completed
Condition(s):Chronic Myelogenous Leukemia – Chronic PhaseLast Updated:September 7, 2023Active, not recruiting
Condition(s):Chronic Myeloid LeukemiaLast Updated:April 6, 2023Completed
Condition(s):Aging; PainLast Updated:December 31, 2014Completed
Condition(s):Relapsed and/or Refractory Multiple Myeloma; Plasma Cell Leukemia in RelapseLast Updated:June 8, 2023Recruiting
Condition(s):Chronic Myeloid LeukemiaLast Updated:November 17, 2022Completed
Condition(s):Type II Diabetes Mellitus Without Mention of ComplicationLast Updated:June 25, 2014Unknown status
Condition(s):Transient Hypothyroxinemia of Prematurity (THOP)Last Updated:April 24, 2019Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.